Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition

Haematologica

Volumn 93, Issue 6, 2008, Pages 842-850

  Khan, Aneire E ^a   Gallo, Valentina ^a   Linseisen, Jakob ^b   Kaaks, Rudolf ^b   Rohrmann, Sabine ^c   Raaschou Nielsen, Ole ^d   Tjønneland, Anne ^d   Johnsen, Hans E ^e   Overvad, Kim ^e   Bergmann, Manuela M ^f   Boeing, Heiner ^f   Benetou, Vasiliki ^g   Psaltopoulou, Theodora ^g   Trichopoulou, Antonia ^g   Masala, Giovanna ^h   Mattiello, Amalia ⁱ   Grioni, Sara ^j   Tumino, Rosario ^k   Vermeulen, Roel C H ^l   Peeters, Petra H M ^l   Bueno de Mesquita, H Bas ^m   Ros, Martine M ^m   Lund, Eiliv ⁿ   Ardanaz, Eva ^o   Chirlaque, María Dolores ^p   Jakszyn, Paula ^q   Larrañaga, Nerea ^r   Losada, Adamina ^s   Becker, Nikolaus ^b   Nieters, Alexandra ^b   Martínez García, Carmen ^t   Ågren, Åsa ^u   Hallmans, Göran ^u   Berglund, Göran ^v   Manjer, Jonas ^v   Allen, Naomi E ^w   Key, Timothy J ^w   Bingham, Sheila ^x   Khaw, Kay Tee ^x   Slimani, Nadia ^y   Ferrari, Pietro ^y   Boffetta, Paolo ^y   Norat, Teresa ^a   Vineis, Paolo ^a   Riboli, Elio ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k CIVILE M P AREZZO HOSPITAL   (Italy)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁿ UNIVERSITY OF TROMSØ   (Norway)

^o INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^p DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^r Department of Public Health of Gipuzkoa ^*  (Spain)

^s Public Health and Planning Directorate   (Spain)

^t ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^u UMEÅ UNIVERSITY   (Sweden)

^v LUND UNIVERSITY HOSPITAL   (Sweden)

^w UNIVERSITY OF OXFORD   (United Kingdom)

^x UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^y INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

Cohort study; Diabetes; Non Hodgkin's lymphoma

Indexed keywords

INSULIN;

ADULT; ARTICLE; CANCER RISK; CLINICAL ASSESSMENT; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; HEREDITY; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROPORTIONAL HAZARDS MODEL; SELF REPORT; STATISTICAL SIGNIFICANCE;

EID: 44949098056     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12297     Document Type: Article

References (48)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
2. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120[Suppl 12]:1-39.
3. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120[Suppl 12]:40-61.
4. Durie BG. The epidemiology of multiple myeloma. Semin Hematol 200; 38[2 Suppl 3]:1-5.
5. Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997; 89:314-8.
6. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
7. Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol 2000; 12:383-94.
8. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002; 56:223-34.
9. Engels EA, Cerhan JR, Linet MS, Cozen W, Colt JS, Davis S, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005;162:1153-61.
10. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2005; 98:51-60.
11. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997;241:471-5.
12. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000;49:32-8.
13. Narayan KM, Bowman BA, Engelgau ME. Prevention of type 2 diabetes. Br Med J 2001;323:63-4.
14. Chow WH, Gridley G, Nyren O, Linet MS, Ekbom A, Fraumeni JF Jr, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995;87:930-1.
15. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89:1360-5.
16. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
17. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006;118:2105-9.
18. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
19. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164-79.
20. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
21. Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-9.
22. Cartwright RA, McKinney PA, O'Brien C, Richards ID, Roberts B, Lauder I, et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 1988; 12:81-8.
23. Fortuny J, Benavente Y, Bosch R, Garcia-Villanueva M, de Sevilla AF, de Sanjosé S. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer 2005;41:1782-7.
24. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435-41.
25. Natazuka T, Manabe Y, Kono M, Murayama T, Matsui T, Chihara K. Association between non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. Br Med J 1994;309:1269.
26. Vineis P, Crosignani P, Sacerdote C, Fontana A, Masala G, Miligi L, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54:431-6.
27. Tavani A, La VC, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 2000;9:59-64.
28. Zahm SH, Blair A, Cantor KP, Fraumeni JF Jr. Non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. Other American studies fail to confirm an association. Br Med J 1995;310:1009-10.
29. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992;52[19 Suppl]:5510s-5s.
30. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
31. Jaffe ES, Harris N, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. 2001. Lyon, IARC Press.
32. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
33. World Health Organization. BMI Classification. 2007.
34. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med 2006;38:34-41.
35. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzalez-Sanchez JL, Seclen S, Villena A, et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006;29:685-91.
36. Ragozzino MW, Melton LJ III, Palumbo PJ, Chu CP. Risk of lymphoma in individuals with diabetes mellitus. J Chronic Dis 1983;36:363-5.
37. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28.
38. Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006;108:292-6.
39. Landgren O, Gridley G, Check D, Caporaso NE, Morris BL. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007;139:791-8.
40. Wolford JK, Colligan PB, Gruber JD, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab 2003;80:338-43.
41. Stephens JW, Hurel SJ, Cooper JA, Acharya J, Miller GJ, Humphries SE. A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. Mol Genet Metab 2004;82:180-6.
42. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, et al. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 2005;28:2007-12.
43. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
44. Feurino LW, Zhang Y, Bharadwaj U, Zhang R, Li F, Fisher WE, et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther 2007 22;6.
45. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 2006;15:2285-91.
46. Parfienczyk A, Kiersnowska-Rogowska B, Rogowski F. [Interleukin-6 and interleukin-12 blood levels in patients with chronic B-cell lymphocytic leukemia]. Pol Merkur Lekarski 2004;16:157-61.
47. Zheng Z, Venkatapathy S, Rao G, Harrington CA. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 2002;16:2429-37.
48. Duek A, Shvidel L, Braester A, Berrebi A. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J 2006;8:828-31.